Skip to main content

Table 4 Comparison between patients with and without nephrolithiasis (clinical characteristics)

From: Nephrolithiasis in gout: prevalence and characteristics of Brazilian patients

 Nephrolithiasis (N = 43)Without Nephrolithiasis (N = 80)P Value
Male gender43 (100%)72 (90.0%)0.049
Skin color/race: white37 (86.0%)65 (81.2%)0.500
Age (years)61.3 ± 9.763.8 ± 9.30.161
Age of onset of disease (years)42.3 ± 11.446.4 ± 12.70.080
Duration of disease (years)19.0 ± 10.817.8 ± 10.40.502
 < 5 years1 (9.1%)*10 (90.9%)*0.168†
 5–15 years19 (38.0%)*31 (62.0%)*
 > 15 years23 (37.1%)*39 (62.9%)*
Tophi24 (55.8%)45 (56.2%)0.963
Underexcretion of uric acid38 (88.4%)72 (91.4%)0.624
Alcohol use disorder36 (83.7%)54 (67.5%)0.053
 Current9 (20.9%)14 (17.5%)0.642
 Past27 (62.8%)40 (50.0%)0.174
Smoking history25 (58.1%)38 (47.5%)0.260
 Current2 (4.7%)8 (10.0%)0.491
 Past23 (53.5%)30 (37.5%)0.088
Medication
 Allopurinol19 (44.2%)26 (32.5%)0.199
 Benzbromarone21 (48.8%)55 (68.8%)0.030
 Potassium citrate13 (30.2%)Zero< 0.001
 Colchicine15 (34.9%)17 (21.2%)0.100
 Glucocorticoids2 (4.7%)5 (6.2%)1.000
 NSAIDs23 (53.5%)41 (51.2%)0.813
 Antidiabetic medication10 (23.3%)8 (10.0%)0.047
 Antihypertensives34 (79.1%)58 (72.5%)0.424
 Lipid-lowering medication15 (34.9%)10 (12.5%)0.003
  1. Data are expressed as the total (%) or the mean ± SD, unless otherwise stated
  2. NSAIDs nonsteroidal anti-inflammatory drugs
  3. * Percentage for each subgroup
  4. p value for the comparison among the three disease duration subgroups